Immuron Showcases Novel Immunotherapies at Conference

Immuron Limited (AU:IMC) has released an update.

Immuron Limited’s CEO, Steven Lydeamore, recently presented at the Emerging Growth Conference, showcasing the company’s advancements in developing oral immunotherapies like Travelan® for preventing travelers’ diarrhea. Immuron’s unique technology leverages hyper-immune bovine colostrum to produce polyclonal antibodies targeting various infectious diseases, including a promising investigational drug, IMM-529, for Clostridioides difficile infection.

For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.